Cerca una sperimentazione clinica
Altra/e opzione/i di ricerca
8 Risultato/i
Sperimentazione in fase di reclutamento
= 
; Sperimentazione in corso
= 
; Finanziato da un ente associato a IRDiRC = 
; Membro di una ERN = 
Sperimentazioni cliniche nazionali
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
A randomized (1:1), double-blind, multi-center, placebo controlled study evaluating intensive chemotherapy with or without Glasdegib (PF-04449913) or Azacitidine with or without Glasdegib in patients with previously untreated acute myeloid leukemia (phase 3) - AT
Institution: Information not provided - AT
AUSTRIA
WIEN
WIEN
A phase 2, double-blind, randomized safety and efficacy study of Glasdegib (PF-04449913) versus placebo in patients with Myelofibrosis previously treated with ruxolitinib - AT
Allgemeines Krankenhaus der Stadt Wien
Klinische Abteilung für Hämatologie und Hämostaseologie
SPAGNA
Andalucía
SEVILLA
GLAS: A phase Ib/IIa pilot trial of the oral Hedgehog Signalling Inhibitor, Glasdegib, in Patients with sclerotic chronic graft-versus-host disease refractory to second-line treatment - ES
Hospital Universitario Virgen del Rocío
Unidad de Hematología
SPAGNA
Madrid
ADDRESS: NOT PROVIDED - ES
A randomized (1:1), double-blind, multi-center, placebo controlled study evaluating intensive chemotherapy with or without Glasdegib (PF-04449913) or Azacitidine with or without Glasdegib in patients with previously untreated acute myeloid leukemia - ES
Institution: Information not provided - ES
SPAGNA
Madrid
MADRID
GEINOGLAS: Phase Ib/II Multicentric Study Combining Glasdegib with temozolomide in patients with newly diagnosed Glioblastoma, safety and preliminary efficacy for the combination - ES
Hospital Universitario Ramón y Cajal
Servicio de Oncología Médica
STATI UNITI
Alabama
BIRMINGHAM
A Randomized, Double-blind Phase 1b/2 Study Of Pf-04449913 (Glasdegib) In Combination With Azacitidine In Patients With Previously Untreated Intermediate-2 Or High-risk Myelodysplastic Syndrome, Acute Myeloid Leukemia With 20-30% Blasts And Multi-lineage Dysplasia, Or Chronic Myelomonocytic Leukemia - US
University of Alabama at Birmingham
STATI UNITI
Washington
ADDRESS: NOT PROVIDED - US
A Phase 2, Double-blind, Randomized Safety And Efficacy Study Of Glasdegib (Pf-04449913) Versus Placebo In Patients With Myelofibrosis Previously Treated With Ruxolitinib - US
Institution: Information not provided - US
Sperimentazioni cliniche internazionali
STATI UNITI
New York
NEW YORK